Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
So Intellia just got the FDA to lift the clinical hold on their MAGNITUDE Phase 3 trial for nexiguran ziclumeran - that's the ATTR cardiomyopathy drug they've been working on. The hold was put in place back in October after some liver enzyme concerns in one patient, but looks like they've worked through that.
What's interesting is they already got the hold on their MAGNITUDE-2 trial resolved in January, so now both trials can keep moving forward. CEO mentioned they're focused on finishing enrollment in both programs. Stock's up 3.56% to $14.27 in pre-market, which makes sense - any time the FDA lifts a clinical hold it's generally good news for biotech companies pushing through Phase 3.
They've had some bumps in the road with this one, but seems like the momentum is back. Worth watching how enrollment progresses from here.